Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen acquired R&D Technology Rights — Accumulated Amortization ($M) ($M)
Form 10-Q / 10-K Goodwill and Other Intangible Assets Note (XBRL)
Latest, FY2025
1,305
Period ended Dec 31, 2025
Change on a year earlier
+5.7%
1,235 in FY2024
History
11 years
Since FY2015
Sources
11
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Acquired R&D Technology Rights — Accumulated Amortization ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,305 | +5.7% | Form 10-Q (filed 2026-08-05) ↗ |
| FY2024 | Dec 31, 2024 | 1,235 | +0.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 1,228 | +3.2% | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 1,190 | +5.0% | Form 10-K (filed 2024-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 1,133 | +6.4% | Form 10-K (filed 2023-02-09) ↗ |
| FY2020 | Dec 31, 2020 | 1,065 | +12.5% | Form 10-K (filed 2022-02-16) ↗ |
| FY2019 | Dec 31, 2019 | 947 | +8.6% | Form 10-Q (filed 2020-05-01) ↗ |
| FY2018 | Dec 31, 2018 | 872 | +8.5% | Form 10-Q (filed 2019-10-30) ↗ |
| FY2017 | Dec 31, 2017 | 804 | +14.2% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 704 | +10.9% | Form 10-K (filed 2018-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 635 | – | Form 10-K (filed 2017-02-14) ↗ |
Cite this data
StockData. (2026). Amgen Acquired R&D Technology Rights — Accumulated Amortization ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fl_rdtech_accum
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.